20.09
price up icon1.72%   0.34
after-market Handel nachbörslich: 19.05 -1.04 -5.18%
loading
Schlusskurs vom Vortag:
$19.75
Offen:
$20.02
24-Stunden-Volumen:
75,550
Relative Volume:
0.28
Marktkapitalisierung:
$307.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+21.24%
1M Leistung:
-2.29%
6M Leistung:
-13.52%
1J Leistung:
-44.16%
1-Tages-Spanne:
Value
$19.01
$20.71
1-Wochen-Bereich:
Value
$14.65
$21.19
52-Wochen-Spanne:
Value
$6.875
$74.49

Neurogene Inc Stock (NGNE) Company Profile

Name
Firmenname
Neurogene Inc
Name
Telefon
(877) 237-5020
Name
Adresse
535 W 24TH STREET, NEW YORK
Name
Mitarbeiter
107
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
NGNE's Discussions on Twitter

Vergleichen Sie NGNE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NGNE
Neurogene Inc
20.09 307.78M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-16 Herabstufung Robert W. Baird Outperform → Neutral
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-06-11 Eingeleitet Robert W. Baird Outperform
2024-04-29 Eingeleitet Leerink Partners Outperform
2024-03-21 Eingeleitet William Blair Outperform
2024-01-08 Eingeleitet H.C. Wainwright Buy
2024-01-05 Eingeleitet Stifel Buy
2024-01-04 Eingeleitet TD Cowen Outperform
Alle ansehen

Neurogene Inc Aktie (NGNE) Neueste Nachrichten

pulisher
Jun 18, 2025

Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Gains Attention with Promising Gene Therapy for - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Receives Positive Coverage with a $50 Price Tar - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Gains Attention with Promising Gene Therapy for Rett Syndrome | NGNE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 14, 2025

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Neurogene’s (NGNE) Outperform Rating Reaffirmed at BMO Capital Markets - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Neurogene (NGNE) Price Target Raised by BMO Capital | NGNE Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Neurogene Approves Amendments at Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Neurogene price target raised to $26 from $22 at BMO Capital - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Neurogene Inc. (NASDAQ:NGNE) Receives $44.60 Consensus PT from Brokerages - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Neurogene Highlights Gene Therapy Advancements in New Update - TipRanks

Jun 09, 2025
pulisher
Jun 08, 2025

Neurogene Inc. (NASDAQ:NGNE) Stock Position Lifted by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph

Jun 06, 2025
pulisher
Jun 06, 2025

Squarepoint Ops LLC Has $398,000 Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Cuts Stake in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Jun 05, 2025
pulisher
May 30, 2025

Neurogene Reports Q1 2025 Financial Progress and Updates - TipRanks

May 30, 2025
pulisher
May 26, 2025

Northern Trust Corp Buys 5,845 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World

May 26, 2025
pulisher
May 22, 2025

BMO Capital Markets Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) Stock - Defense World

May 22, 2025
pulisher
May 21, 2025

Deutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World

May 21, 2025
pulisher
May 20, 2025

Neurogene (NGNE) Receives Price Target Boost from BMO Capital | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Neurogene (NGNE) Receives Price Target Boost from BMO Capital | NGNE Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Neurogene stock target raised to $22 by BMO Capital - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

ASGCT Roundup: Sarepta, Rocket, Neurogene and the World’s First Tailored CRISPR Therapy - NewsBreak: Local News & Alerts

May 19, 2025
pulisher
May 19, 2025

Neurogene introduces gene therapy monitoring system after patient death - Yahoo Finance

May 19, 2025
pulisher
May 18, 2025

Neurogene (NASDAQ:NGNE) Stock Rating Lowered by Robert W. Baird - Defense World

May 18, 2025
pulisher
May 18, 2025

Baird R W Downgrades Neurogene (NASDAQ:NGNE) to Hold - Defense World

May 18, 2025
pulisher
May 17, 2025

Neurogene presents HLH treatment strategy at ASGCT meeting By Investing.com - Investing.com Nigeria

May 17, 2025
pulisher
May 17, 2025

Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.20 - Defense World

May 17, 2025
pulisher
May 16, 2025

Neurogene Shares Drop After Downgrade From Baird - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga

May 16, 2025
pulisher
May 16, 2025

Neurogene stock downgraded at Baird (NGNE:NASDAQ) - Seeking Alpha

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Downgraded to Neutral with Lowered Price Target | NGNE Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Neurogene presents HLH treatment strategy at ASGCT meeting - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy Complication | NGNE Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Eagle-Tribune

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Baird cuts Neurogene stock rating, lowers price target to $24 By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | NGNE Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Baird cuts Neurogene stock rating, lowers price target to $24 - Investing.com

May 16, 2025
pulisher
May 16, 2025

Q2 Earnings Estimate for Neurogene Issued By HC Wainwright - Defense World

May 16, 2025
pulisher
May 15, 2025

Rett Syndrome treatment Market Is Booming Worldwide 2025-2032 | - openPR.com

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World

May 15, 2025
pulisher
May 13, 2025

Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained | N - GuruFocus

May 13, 2025

Finanzdaten der Neurogene Inc-Aktie (NGNE)

Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Kapitalisierung:     |  Volumen (24h):